Novel Therapy Target in Metastatic Prostate Cancer

Trial Title: Novel Therapy Target in Metastatic Prostate Cancer

NCT ID: NCT05577689

Condition: Prostate Neoplasms

Conditions: Official terms:
Prostatic Neoplasms

Conditions: Keywords:
prostate cancer
multi-omics
organoid

Study type: Observational

Overall status: Not yet recruiting

Study design:

Time perspective: Prospective

Intervention:

Intervention type: Other
Intervention name: Tissue
Description: Tissue will be derived from patients during a standard of care procedure
Arm group label: All patients

Summary: The aim of this study is to use multiomics sequencing to explore the molecular characteristics of metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC). At the same time, mCRPC models will be constructed, including organoids and animal models, serving as a basic and translational research platform to help identify novel drug targets for mPCa.

Detailed description: Although substantial progress in treatments for prostate cancer have been made in the past decades, distant metastasis and drug resistance remained a major cause of prostate cancer-related deaths. The five-year survival rate for men with mPCa was only 30% and all patients with mPCa would inevitably progress to the castration-resistant stage with limited therapeutic chance. In China, the current situation is more worrying, with rapidly increasing PCa incidence and higher proportion of mPCa diagnosed compared with the Western nations (~30% vs ~5%). Multiomics sequencing provides a promising strategy to discover the underlying molecular basis driving metastasis and resistance and identify the new treatment strategies for patients with mCRPC. The candidate drug target revealed by the multiomics sequencing could be further examined in the organoid and animal models, facilitating the clinical application from basic discovery. This study can establish a mCRPC research system to find the molecular mechanism and potential intervention targets of mCRPC, thereby paving the way for the discovery of new treatments for mCRPC patients.

Criteria for eligibility:

Study pop:
Patients with metastatic prostate cancer especially metastatic castration resistant prostate cancer will be recruited for this study.

Sampling method: Non-Probability Sample
Criteria:
Inclusion Criteria: 1. Histologically confirmed prostate cancer 2. metastatic disease confirmed by image examination 3. Patients who can undergo surgery or biopsy for prostate cancer 4. Able to provide informed consent Exclusion Criteria: 1. Patients diagnosed with other types of cancer besides prostate cancer 2. Not accessible to surgery sample 3. Patients fail to provide informed consent 4. Other situation that researchers think are unsuitable for this study

Gender: Male

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Start date: March 1, 2023

Completion date: May 1, 2026

Lead sponsor:
Agency: Fudan University
Agency class: Other

Source: Fudan University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05577689